RS59369B1 - Individualizovane vakcine protiv kancera - Google Patents
Individualizovane vakcine protiv kanceraInfo
- Publication number
- RS59369B1 RS59369B1 RSP20191210A RS59369B1 RS 59369 B1 RS59369 B1 RS 59369B1 RS P20191210 A RSP20191210 A RS P20191210A RS 59369 B1 RS59369 B1 RS 59369B1
- Authority
- RS
- Serbia
- Prior art keywords
- cancer
- individualized vaccines
- individualized
- vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/002576 WO2012159643A1 (en) | 2011-05-24 | 2011-05-24 | Individualized vaccines for cancer |
| EP2012000006 | 2012-01-02 | ||
| EP12723117.3A EP2714071B1 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
| PCT/EP2012/002209 WO2012159754A2 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59369B1 true RS59369B1 (sr) | 2019-11-29 |
Family
ID=50185364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP20191210 RS59369B1 (sr) | 2011-05-24 | 2012-05-23 | Individualizovane vakcine protiv kancera |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP3473267B1 (sr) |
| CY (3) | CY1122110T1 (sr) |
| DK (1) | DK3473267T3 (sr) |
| HR (1) | HRP20191535T1 (sr) |
| ME (1) | ME03498B (sr) |
| PL (2) | PL2714071T3 (sr) |
| RS (1) | RS59369B1 (sr) |
| SI (1) | SI2714071T1 (sr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012261237B2 (en) | 2011-05-24 | 2017-06-01 | BioNTech SE | Individualized vaccines for cancer |
| ME03498B (me) | 2011-05-24 | 2020-04-20 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualizovane vakcine protiv kancera |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| WO1999034015A2 (en) | 1997-12-24 | 1999-07-08 | Imperial Cancer Research Technology Limited | Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment |
| EP1214097B3 (en) | 1999-09-16 | 2011-07-20 | Eisai Inc. | Nucleic acids encoding polyepitope polypeptides |
| EP2305699B1 (de) * | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
| CN100392087C (zh) * | 2001-11-26 | 2008-06-04 | 昆士兰大学 | 黄病毒疫苗输送系统 |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP3699266A1 (en) * | 2010-05-14 | 2020-08-26 | The General Hospital Corporation | Neoantigen specific cytotoxic t cells for use in treating cancer |
| ME03498B (me) | 2011-05-24 | 2020-04-20 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualizovane vakcine protiv kancera |
-
2012
- 2012-05-23 ME MEP-2019-237A patent/ME03498B/me unknown
- 2012-05-23 EP EP18199105.0A patent/EP3473267B1/en active Active
- 2012-05-23 PL PL12723117T patent/PL2714071T3/pl unknown
- 2012-05-23 RS RSP20191210 patent/RS59369B1/sr unknown
- 2012-05-23 EP EP12723117.3A patent/EP2714071B1/en active Active
- 2012-05-23 DK DK18199105.0T patent/DK3473267T3/da active
- 2012-05-23 EP EP21168360.2A patent/EP3892295B1/en active Active
- 2012-05-23 SI SI201231660T patent/SI2714071T1/sl unknown
- 2012-05-23 PL PL18199105T patent/PL3473267T3/pl unknown
- 2012-05-23 EP EP23169466.2A patent/EP4223311A1/en active Pending
-
2019
- 2019-08-27 HR HRP20191535 patent/HRP20191535T1/hr unknown
- 2019-09-18 CY CY20191100986T patent/CY1122110T1/el unknown
-
2021
- 2021-11-02 CY CY20211100945T patent/CY1124685T1/el unknown
-
2023
- 2023-05-25 CY CY20231100248T patent/CY1126128T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2714071T1 (sl) | 2019-11-29 |
| CY1124685T1 (el) | 2022-07-22 |
| EP3473267B1 (en) | 2021-09-08 |
| PL3473267T3 (pl) | 2022-01-10 |
| HRP20191535T1 (hr) | 2019-11-29 |
| CY1122110T1 (el) | 2020-11-25 |
| EP4223311A1 (en) | 2023-08-09 |
| EP2714071A2 (en) | 2014-04-09 |
| CY1126128T1 (el) | 2023-11-15 |
| EP3892295B1 (en) | 2023-04-26 |
| DK3473267T3 (da) | 2021-10-18 |
| ME03498B (me) | 2020-04-20 |
| EP3473267A1 (en) | 2019-04-24 |
| EP2714071B1 (en) | 2019-07-10 |
| EP3892295A1 (en) | 2021-10-13 |
| PL2714071T3 (pl) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201306944B (en) | Individualized vaccines for cancer | |
| HK1197182A1 (en) | Cancer immunotherapy | |
| EP2714073A4 (en) | ANTI-CANCER ANTIGEN GENE VACCINE IN SITU | |
| PL2758630T3 (pl) | Regulowany system do szczelinowania | |
| HK1199448A1 (en) | Disubstituted 5-fluoro-pyrimidines 5-- | |
| IL231043A0 (en) | vaccine | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| GB201119999D0 (en) | Vaccine | |
| HK1201176A1 (en) | Antigen presenting cancer vaccine | |
| EP2763699A4 (en) | VACCINE | |
| HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
| ZA201306245B (en) | Combination vaccines | |
| EP2771453A4 (en) | DIATOM-BASED VACCINES | |
| PL2729158T3 (pl) | Szczepionki przeciwko Chlamydia | |
| SI2714071T1 (sl) | Individualizirana cepiva proti raku | |
| GB201120000D0 (en) | Vaccine | |
| GB201107549D0 (en) | Cancer vaccine | |
| GB201108982D0 (en) | Vaccines | |
| GB201108984D0 (en) | Vaccines | |
| GB201108986D0 (en) | Vaccines | |
| GB201121647D0 (en) | Vaccine | |
| GB201108256D0 (en) | Vaccine |